Could a common drug tame a rare brain artery disorder?
NCT ID NCT07634120
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot trial tests whether sirolimus, an anti-inflammatory drug, can reduce artery wall swelling in people with vertebrobasilar dolichoectasia (VBD), a condition where arteries at the base of the brain become enlarged and twisted. Twelve participants will take sirolimus daily for 6 months, and doctors will use advanced 5T MRI scans to track changes. The goal is to see if the drug can calm inflammation and possibly slow disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sirolimus (an oral drug that calms inflammation)
- What this could lead to
- If it works, this could point toward a treatment to slow or stop the progression of vertebrobasilar dolichoectasia, a rare artery condition.
- What could go wrong
- This is a very small pilot study with only 12 people, so results may not apply widely. It is also early-stage and may not show clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VERTEBROBASILAR DOLICHOECTASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200040, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.